STOCK TITAN
  1. Home
  2. Sec-filings
  3. TBPH
  4. [Form 4] Theravance Biopharma, Inc. Insider Trading Activity

Director Dean J. Mitchell granted shares and options at Theravance (NASDAQ: TBPH)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Theravance Biopharma director Dean J. Mitchell received equity compensation, gaining 6,009 ordinary shares and a grant of options for 13,398 ordinary shares. The options have an exercise price of $16.64 per share and vest monthly, with remaining unvested options vesting by the next annual shareholder meeting if service continues.

Positive

  • None.

Negative

  • None.
Insider MITCHELL DEAN J
Role null
Type Security Shares Price Value
Grant/Award Share Option (Right to Buy) 13,398 $0.00 --
Grant/Award Ordinary Shares 6,009 $0.00 --
Holdings After Transaction: Share Option (Right to Buy) — 13,398 shares (Direct, null); Ordinary Shares — 97,213 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Share grant 6,009 ordinary shares Equity award to Dean J. Mitchell
Options granted 13,398 options Share Option (Right to Buy) grant
Exercise price $16.64 per share Strike price of granted options
Shares after grant 97,213 ordinary shares Total direct holdings after transaction
Option expiration June 11, 2036 End of exercise period for options
Vesting schedule 1/12 monthly Portion of option shares vest each month of service
Share Option (Right to Buy) financial
"security_title: "Share Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "16.6400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
continuous month of service other
"when optionee completes each continuous month of service following the grant date"
annual meeting of the company's shareholders other
"shall vest on the date of the next annual meeting of the company's shareholders"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MITCHELL DEAN J
(Last)(First)(Middle)
C/O THERAVANCE BIOPHARMA US, LLC
901 GATEWAY BLVD
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares06/12/2026A6,009A$097,213D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (Right to Buy)$16.6406/12/2026A13,398 (1)06/11/2036Ordinary Shares13,398$013,398D
Explanation of Responses:
1. This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date.
/s/ Brett A. Grimaud, Attorney-in-Fact06/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Theravance Biopharma (TBPH) director Dean J. Mitchell receive in this Form 4?

Dean J. Mitchell received 6,009 ordinary shares and a grant of options for 13,398 ordinary shares as equity compensation, according to the Form 4 insider transaction data.

What is the exercise price of the new Theravance Biopharma (TBPH) options?

The newly granted options have an exercise price of $16.64 per share. This is the price at which Dean J. Mitchell can buy Theravance Biopharma ordinary shares under the option grant.

How many Theravance Biopharma (TBPH) shares does Dean J. Mitchell hold after this grant?

After the grant, Dean J. Mitchell directly holds 97,213 ordinary shares of Theravance Biopharma. This total reflects his position following the 6,009-share award reported in the Form 4.

How do the new Theravance Biopharma (TBPH) options vest for Dean J. Mitchell?

The options vest as to 1/12 of the shares each month of continuous service following the grant date, with any remaining unvested options vesting on the date of the next annual shareholder meeting if he remains in service.

When do the newly granted Theravance Biopharma (TBPH) options expire?

The granted options expire on June 11, 2036. After that date, Dean J. Mitchell will no longer be able to exercise these options to acquire ordinary shares at the stated exercise price.